Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis

(2013) A. Fantin et al.   BLOOD

Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling

(2013) Corentin Herbert et al.   CANCER CELL

Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties

(2013) Françoise Bono et al.   CANCER CELL

Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1

(2013) Jia Lu et al.   CANCER CELL

Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy

(2013) D. Gerald et al.   CANCER RESEARCH

Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma

(2013) Matija Snuderl et al.   CELL

Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance

(2013) A. Jahangiri et al.   CLINICAL CANCER RESEARCH

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

(2013) Cora N. Sternberg et al.   EUROPEAN JOURNAL OF CANCER

Angiopoietin signaling in the vasculature

(2013) Lauri Eklund et al.   EXPERIMENTAL CELL RESEARCH

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Macrophage biology in development, homeostasis and disease

(2013) Thomas A. Wynn et al.   NATURE

Spatial regulation of VEGF receptor endocytosis in angiogenesis

(2013) Masanori Nakayama et al.   NATURE CELL BIOLOGY

Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease

(2013) S. Goel et al.   Cold Spring Harbor Perspectives in Medicine

Anti-VEGF Therapies in the Clinic

(2013) K. L. Meadows et al.   Cold Spring Harbor Perspectives in Medicine

PlGF: A Multitasking Cytokine with Disease-Restricted Activity

(2013) M. Dewerchin et al.   Cold Spring Harbor Perspectives in Medicine

Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth

(2012) M. A. Abengozar et al.   BLOOD

Formation of a PKC / -catenin complex in endothelial cells promotes angiopoietin-1-induced collective directional migration and angiogenic sprouting

(2012) M. Oubaha et al.   BLOOD

Semaphorin 6A regulates angiogenesis by modulating VEGF signaling

(2012) M. Segarra et al.   BLOOD

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

(2012) Vesselina G. Cooke et al.   CANCER CELL

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success

(2012) Cristina Branco-Price et al.   CANCER CELL

Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

(2012) Farbod Shojaei   CANCER LETTERS

Angiopoietins in angiogenesis

(2012) Ernesta Fagiani et al.   CANCER LETTERS

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

(2012) C. Daly et al.   CANCER RESEARCH

Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials

(2012) John R. Mackey et al.   CANCER TREATMENT REVIEWS

Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications

(2012) D. A. Kirschmann et al.   CLINICAL CANCER RESEARCH

Determination of Endothelial Stalk versus Tip Cell Potential during Angiogenesis by H2.0-like Homeobox-1

(2012) Shane P. Herbert et al.   CURRENT BIOLOGY

VEGF signaling inside vascular endothelial cells and beyond

(2012) Anne Eichmann et al.   CURRENT OPINION IN CELL BIOLOGY

S1P1 inhibits sprouting angiogenesis during vascular development

(2012) A. B. Shoham et al.   DEVELOPMENT

Stalk Cell Phenotype Depends on Integration of Notch and Smad1/5 Signaling Cascades

(2012) Iván M. Moya et al.   DEVELOPMENTAL CELL

The Sphingosine-1-Phosphate Receptor S1PR1 Restricts Sprouting Angiogenesis by Regulating the Interplay between VE-Cadherin and VEGFR2

(2012) Konstantin Gaengel et al.   DEVELOPMENTAL CELL

ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway

(2012) Bruno Larrivée et al.   DEVELOPMENTAL CELL

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

(2012) Moritz Felcht et al.   JOURNAL OF CLINICAL INVESTIGATION

Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

(2012) Rodryg Ramlau et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

(2012) Hans-Joachim Schmoll et al.   JOURNAL OF CLINICAL ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

(2012) Alicia S Chung et al.   JOURNAL OF PATHOLOGY

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

(2012) Mallika Singh et al.   JOURNAL OF PATHOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

(2012) Diether Lambrechts et al.   LANCET ONCOLOGY

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY

Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling

(2012) Rui Benedito et al.   NATURE

Pathological neoangiogenesis depends on oxidative stress regulation by ATM

(2012) Yuji Okuno et al.   NATURE MEDICINE

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

(2012) Annamaria Rapisarda et al.   Nature Reviews Clinical Oncology

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

Orchestral actions of angiopoietin-1 in vascular regeneration

(2012) Gou Young Koh   TRENDS IN MOLECULAR MEDICINE

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

VEGFR-1 Mediates Endothelial Differentiation and Formation of Blood Vessels in a Murine Model of Infantile Hemangioma

(2011) Elisa Boscolo et al.   AMERICAN JOURNAL OF PATHOLOGY

Developmental and Pathological Angiogenesis

(2011) Alicia S. Chung et al.   Annual Review of Cell and Developmental Biology

Pericyte-Derived Sphinogosine 1-Phosphate Induces the Expression of Adhesion Proteins and Modulates the Retinal Endothelial Cell Barrier

(2011) Paul G. McGuire et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7-dependent pathway

(2011) H. K. Lee et al.   BLOOD

The VEGF-regulated transcription factor HLX controls the expression of guidance cues and negatively regulates sprouting of endothelial cells

(2011) J. Testori et al.   BLOOD

HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF

(2011) Charlotte Rolny et al.   CANCER CELL

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia

(2011) Thomas Schmidt et al.   CANCER CELL

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo

(2011) J.-L. Li et al.   CANCER RESEARCH

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

(2011) Dana D. Hu-Lowe et al.   CANCER RESEARCH

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

(2011) W.-K. You et al.   CANCER RESEARCH

Basic and Therapeutic Aspects of Angiogenesis

(2011) Michael Potente et al.   CELL

Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis: Figure 1.

(2011) Michele De Palma et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

(2011) Leonard Saltz et al.   Clinical Colorectal Cancer

Distinct Cellular Mechanisms of Blood Vessel Fusion in the Zebrafish Embryo

(2011) Lukas Herwig et al.   CURRENT BIOLOGY

Robo4-dependent Slit signaling stabilizes the vasculature during pathologic angiogenesis and cytokine storm

(2011) Nyall R London et al.   CURRENT OPINION IN HEMATOLOGY

The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins

(2011) A. Fantin et al.   DEVELOPMENT

Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo

(2011) J. Krueger et al.   DEVELOPMENT

Coordinating cell behaviour during blood vessel formation

(2011) I. Geudens et al.   DEVELOPMENT

Robo4 Maintains Vessel Integrity and Inhibits Angiogenesis by Interacting with UNC5B

(2011) Alexander W. Koch et al.   DEVELOPMENTAL CELL

Endothelial laminins underlie the tip cell microenvironment

(2011) Jan Kitajewski   EMBO REPORTS

Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo

(2011) Denise Stenzel et al.   EMBO REPORTS

Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism

(2011) J. Kim et al.   GENES & DEVELOPMENT

Angiopoietin-1/Tie2 Signal Augments Basal Notch Signal Controlling Vascular Quiescence by Inducing Delta-Like 4 Expression through AKT-mediated Activation of β-Catenin

(2011) Jianghui Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Angiopoietin-1 is essential in mouse vasculature during development and in response to injury

(2011) Marie Jeansson et al.   JOURNAL OF CLINICAL INVESTIGATION

The yin, the yang, and the Angiopoietin-1

(2011) Pipsa Saharinen et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma

(2011) Tina Cascone et al.   JOURNAL OF CLINICAL INVESTIGATION

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

(2011) Beth Y. Karlan et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis

(2011) Yukiji Takeda et al.   NATURE

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

(2011) Benjamin Beck et al.   NATURE

Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase

(2011) Virginia Guarani et al.   NATURE

VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling

(2011) Tuomas Tammela et al.   NATURE CELL BIOLOGY

Central nervous system pericytes in health and disease

(2011) Ethan A Winkler et al.   NATURE NEUROSCIENCE

Cerebrovascular disorders: molecular insights and therapeutic opportunities

(2011) Erik Storkebaum et al.   NATURE NEUROSCIENCE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

The Neurovascular Link in Health and Disease: Molecular Mechanisms and Therapeutic Implications

(2011) Annelies Quaegebeur et al.   NEURON

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transdifferentiation of glioblastoma cells into vascular endothelial cells

(2011) Y. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis

(2011) Pipsa Saharinen et al.   TRENDS IN MOLECULAR MEDICINE

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction

(2010) A. Fantin et al.   BLOOD

Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage

(2010) Young Jun Koh et al.   CANCER CELL

Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization

(2010) Denis Tvorogov et al.   CANCER CELL

Stage II and Stage III Colon Cancer

(2010) Benoît Rousseau et al.   CANCER JOURNAL

Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats

(2010) Raisa Serpi et al.   CARDIOVASCULAR RESEARCH

Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation

(2010) Maija Bry et al.   CIRCULATION

Dynamics of endothelial cell behavior in sprouting angiogenesis

(2010) Hanna M Eilken et al.   CURRENT OPINION IN CELL BIOLOGY

Eph/ephrin molecules--a hub for signaling and endocytosis

(2010) M. E. Pitulescu et al.   GENES & DEVELOPMENT

Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding

(2010) M. L. Bochenek et al.   JOURNAL OF CELL SCIENCE

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials

(2010) David Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis

(2010) Suphansa Sawamiphak et al.   NATURE

Tumour stem cells switch sides

(2010) Victoria L. Bautch   NATURE

Chronic DLL4 blockade induces vascular neoplasms

(2010) Minhong Yan et al.   NATURE

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

(2010) Yingdi Wang et al.   NATURE

Glioblastoma stem-like cells give rise to tumour endothelium

(2010) Rong Wang et al.   NATURE

Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting

(2010) Lars Jakobsson et al.   NATURE CELL BIOLOGY

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

(2009) Sonja Loges et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization

(2009) Massimiliano Mazzone et al.   CELL

Local Guidance of Emerging Vessel Sprouts Requires Soluble Flt-1

(2009) John C. Chappell et al.   DEVELOPMENTAL CELL

Nrarp Coordinates Endothelial Notch and Wnt Signaling to Control Vessel Density in Angiogenesis

(2009) Li-Kun Phng et al.   DEVELOPMENTAL CELL

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Real-time imaging reveals the single steps of brain metastasis formation

(2009) Yvonne Kienast et al.   NATURE MEDICINE

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

(2009) F. Shojaei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

(2008) T. P. Padera et al.   MOLECULAR CANCER THERAPEUTICS

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

(2008) A. Claes et al.   MOLECULAR CANCER THERAPEUTICS

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

(2008) Tuomas Tammela et al.   NATURE

Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability

(2008) Christopher A Jones et al.   NATURE MEDICINE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE